Targeting the C-Terminal Domain Small Phosphatase 1
暂无分享,去创建一个
Young Jun Kim | Harikrishna Reddy Rallabandi | P. Ganesan | Palanivel Ganesan | Young Jun Kim | H. Rallabandi
[1] F. Goldwasser,et al. Investigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeutics , 2015, Expert opinion on investigational drugs.
[2] O. Jänne,et al. Small carboxyl‐terminal domain phosphatase 2 attenuates androgen‐dependent transcription , 2006, The EMBO journal.
[3] Diane Joseph-McCarthy,et al. Ensemble-Based Docking Using Biased Molecular Dynamics , 2014, J. Chem. Inf. Model..
[4] Ivet Bahar,et al. Pharmmaker: Pharmacophore modeling and hit identification based on druggability simulations , 2019, Protein science : a publication of the Protein Society.
[5] D. Reinberg,et al. FCP 1 , a Phosphatase Specific for the Heptapeptide Repeat of the Largest Subunit of RNA Polymerase II , Stimulates Transcription Elongation , 2002 .
[6] Ruben Abagyan,et al. Ligand-biased ensemble receptor docking (LigBEnD): a hybrid ligand/receptor structure-based approach , 2017, Journal of Computer-Aided Molecular Design.
[7] Richard D. Taylor,et al. Improved protein–ligand docking using GOLD , 2003, Proteins.
[8] Claudio N. Cavasotto,et al. Normal mode-based approaches in receptor ensemble docking. , 2012, Methods in molecular biology.
[9] Anthony C. Bishop,et al. Targeting a Cryptic Allosteric Site for Selective Inhibition of the Oncogenic Protein Tyrosine Phosphatase Shp2 , 2014, Biochemistry.
[10] Pavan V. Payghan,et al. Use of molecular dynamics simulations in structure-based drug discovery. , 2019, Current pharmaceutical design.
[11] David S. Goodsell,et al. Protein Flexibility in Virtual Screening: The BACE-1 Case Study , 2012, J. Chem. Inf. Model..
[12] Qian Wu,et al. Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway , 2020, Acta Pharmacologica Sinica.
[13] P. Lijnzaad,et al. FOXO target gene CTDSP2 regulates cell cycle progression through Ras and p21Cip1/Waf1 , 2015, The Biochemical journal.
[14] Jessica Lynn Grey,et al. Challenges and opportunities for new protein crystallization strategies in structure-based drug design , 2010, Expert opinion on drug discovery.
[15] Julio Caballero,et al. Is It Reliable to Use Common Molecular Docking Methods for Comparing the Binding Affinities of Enantiomer Pairs for Their Protein Target? , 2016, International journal of molecular sciences.
[16] Yanli Wang,et al. Structure-Based Virtual Screening for Drug Discovery: a Problem-Centric Review , 2012, The AAPS Journal.
[17] N. Subbarao,et al. Allosteric inhibition of topoisomerase I by pinostrobin: Molecular docking, spectroscopic and topoisomerase I activity studies. , 2017, Journal of photochemistry and photobiology. B, Biology.
[18] Wei Zhang,et al. Identification of the Binding Site of an Allosteric Ligand Using STD‐NMR, Docking, and CORCEMA‐ST Calculations , 2013, ChemMedChem.
[19] Yanjie Wei,et al. DeepBindRG: a deep learning based method for estimating effective protein–ligand affinity , 2019, PeerJ.
[20] A. Mbonye,et al. Introducing rapid diagnostic tests for malaria into drug shops in Uganda: design and implementation of a cluster randomized trial , 2014, Trials.
[21] A. Brivanlou,et al. Dephosphorylation of the Linker Regions of Smad1 and Smad2/3 by Small C-terminal Domain Phosphatases Has Distinct Outcomes for Bone Morphogenetic Protein and Transforming Growth Factor-β Pathways* , 2006, Journal of Biological Chemistry.
[22] Sina Shahbazmohamadi,et al. Assemble-And-Match: A Novel Hybrid Tool for Enhancing Education and Research in Rational Structure Based Drug Design , 2018, Scientific Reports.
[23] P. Lin,et al. Functional characterization of small CTD phosphatases. , 2007, Methods in molecular biology.
[24] J. Tuszynski,et al. Software for molecular docking: a review , 2017, Biophysical Reviews.
[25] Arthur Christopoulos,et al. Allosteric targeting of receptor tyrosine kinases , 2014, Nature Biotechnology.
[26] Li Li,et al. Structure-Based Drug Design Strategies and Challenges. , 2018, Current topics in medicinal chemistry.
[27] Thomas Lengauer,et al. A fast flexible docking method using an incremental construction algorithm. , 1996, Journal of molecular biology.
[28] G. Stein,et al. The role of Runx2 in facilitating autophagy in metastatic breast cancer cells , 2018, Journal of cellular physiology.
[29] C. Lima,et al. The structure of Fcp1, an essential RNA polymerase II CTD phosphatase. , 2008, Molecular cell.
[30] Martin Zacharias,et al. Monte Carlo replica‐exchange based ensemble docking of protein conformations , 2017, Proteins.
[31] Mengang Xu,et al. Utilizing Experimental Data for Reducing Ensemble Size in Flexible-Protein Docking , 2012, J. Chem. Inf. Model..
[32] J. An,et al. Structure-based virtual screening of chemical libraries for drug discovery. , 2006, Current opinion in chemical biology.
[33] L. S. Churchman,et al. The code and beyond: transcription regulation by the RNA polymerase II carboxy-terminal domain , 2017, Nature Reviews Molecular Cell Biology.
[34] Y. Chuman,et al. Identification of a Specific Inhibitor of Human Scp1 Phosphatase Using the Phosphorylation Mimic Phage Display Method , 2019, Catalysts.
[35] L. Leibovici,et al. Combination antimicrobial treatment versus monotherapy: the contribution of meta-analyses. , 2009, Infectious disease clinics of North America.
[36] B. Lakshmi,et al. In silico investigations on the binding efficacy and allosteric mechanism of six different natural product compounds towards PTP1B inhibition through docking and molecular dynamics simulations , 2019, Journal of Molecular Modeling.
[37] D. Grigoriadis,et al. Drugability of Extracellular Targets: Discovery of Small Molecule Drugs Targeting Allosteric, Functional, and Subunit-Selective Sites on GPCRs and Ion Channels , 2009, Neuropsychopharmacology.
[38] R. V. van Montfort,et al. Structure-based drug design: aiming for a perfect fit , 2017, Essays in biochemistry.
[39] P Willett,et al. Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.
[40] Youngjun Kim. Emerging Roles of CTD Phosphatases , 2017 .
[41] Maria Laura Bolognesi,et al. Molecular Hybridization as a Tool for Designing Multitarget Drug Candidates for Complex Diseases. , 2019, Current topics in medicinal chemistry.
[42] Ismail Erol,et al. Identification of novel serotonin reuptake inhibitors targeting central and allosteric binding sites: A virtual screening and molecular dynamics simulations study. , 2017, Journal of molecular graphics & modelling.
[43] D. Brömme,et al. A composite docking approach for the identification and characterization of ectosteric inhibitors of cathepsin K , 2017, PloS one.
[44] Olivier Sheik Amamuddy,et al. Integrated Computational Approaches and Tools for Allosteric Drug Discovery , 2020, International journal of molecular sciences.
[45] J. Pratap,et al. Runx2 activates PI3K/Akt signaling via mTORC2 regulation in invasive breast cancer cells , 2014, Breast Cancer Research.
[46] G. Keserű,et al. Structure-based Virtual Screening Approaches in Kinase-directed Drug Discovery. , 2017, Current topics in medicinal chemistry.
[47] J. Lorens,et al. Cellular context–mediated Akt dynamics regulates MAP kinase signaling thresholds during angiogenesis , 2015, Molecular biology of the cell.
[48] Maciej Majewski,et al. Dynamic Undocking: A Novel Method for Structure-Based Drug Discovery. , 2018, Methods in molecular biology.
[49] F. Robert,et al. The RNA Polymerase II CTD: The Increasing Complexity of a Low-Complexity Protein Domain. , 2016, Journal of molecular biology.
[50] Shibo Jiang,et al. From therapeutic antibodies to chimeric antigen receptors (CARs): making better CARs based on antigen-binding domain , 2016, Expert opinion on biological therapy.
[51] Liang Weng,et al. Angiogenesis effect of therapeutic ultrasound on HUVECs through activation of the PI3K-Akt-eNOS signal pathway. , 2015, American journal of translational research.
[52] Eun Jeong Cho,et al. Selective inactivation of a human neuronal silencing phosphatase by a small molecule inhibitor. , 2011, ACS chemical biology.
[53] Woody Sherman,et al. Improving database enrichment through ensemble docking , 2008, J. Comput. Aided Mol. Des..
[54] Hwangseo Park,et al. Two-track virtual screening approach to identify both competitive and allosteric inhibitors of human small C-terminal domain phosphatase 1 , 2017, Journal of Computer-Aided Molecular Design.
[55] J. Greenblatt,et al. FCP1, the RAP74-Interacting Subunit of a Human Protein Phosphatase That Dephosphorylates the Carboxyl-terminal Domain of RNA Polymerase IIO* , 1998, The Journal of Biological Chemistry.
[56] David E. Clark,et al. A comparison of heuristic search algorithms for molecular docking , 1997, J. Comput. Aided Mol. Des..
[57] A. Sali,et al. Structural genomics of protein phosphatases , 2007, Journal of Structural and Functional Genomics.
[58] J. Dixon,et al. A conserved phosphatase cascade that regulates nuclear membrane biogenesis , 2007, Proceedings of the National Academy of Sciences.
[59] J. Tardif,et al. Pharmacogenomics to Revive Drug Development in Cardiovascular Disease , 2016, Cardiovascular Drugs and Therapy.
[60] Sangdun Choi,et al. A Structure-Based Drug Discovery Paradigm , 2019, International journal of molecular sciences.
[61] Kenneth M Merz,et al. Molecular recognition and drug-lead identification: what can molecular simulations tell us? , 2010, Current medicinal chemistry.
[62] Y. Li,et al. Palmitoylated SCP1 is targeted to the plasma membrane and negatively regulates angiogenesis , 2017, eLife.
[63] Jong-Bok Yoon,et al. Solution Structure and Rpn1 Interaction of the UBL Domain of Human RNA Polymerase II C-Terminal Domain Phosphatase , 2013, PloS one.
[64] Geng Wu,et al. ASD: a comprehensive database of allosteric proteins and modulators , 2010, Nucleic Acids Res..
[65] A novel function for p21Cip1 and acetyltransferase p/CAF as critical transcriptional regulators of TGFβ-mediated breast cancer cell migration and invasion , 2012, Breast Cancer Research.
[66] Z. Oltvai,et al. Identification of novel bacterial histidine biosynthesis inhibitors using docking, ensemble rescoring, and whole-cell assays. , 2010, Bioorganic & medicinal chemistry.
[67] I. Ghosh,et al. New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors. , 2012, Current pharmaceutical design.
[68] Shigenori Tanaka,et al. Cosolvent-Based Molecular Dynamics for Ensemble Docking: Practical Method for Generating Druggable Protein Conformations , 2017, J. Chem. Inf. Model..
[69] Ruben Abagyan,et al. Recipes for the Selection of Experimental Protein Conformations for Virtual Screening , 2010, J. Chem. Inf. Model..
[70] Jia Cao,et al. Overexpression of miR-26b-5p regulates the cell cycle by targeting CCND2 in GC-2 cells under exposure to extremely low frequency electromagnetic fields , 2016, Cell cycle.
[71] Tina Ritschel,et al. Current progress in Structure-Based Rational Drug Design marks a new mindset in drug discovery , 2018 .
[72] Ruth Huey,et al. Computational protein–ligand docking and virtual drug screening with the AutoDock suite , 2016, Nature Protocols.
[73] M. Barahona,et al. Prediction of allosteric sites and mediating interactions through bond-to-bond propensities , 2016, Nature Communications.
[74] Sally R. Ellingson,et al. Ensemble-based docking: From hit discovery to metabolism and toxicity predictions. , 2016, Bioorganic & medicinal chemistry.
[75] F. Jiang,et al. Phosphatase activity of small C-terminal domain phosphatase 1 (SCP1) controls the stability of the key neuronal regulator RE1-silencing transcription factor (REST) , 2018, The Journal of Biological Chemistry.
[76] J. Pratap,et al. Role of Runx2 in Crosstalk Between Mek/Erk and PI3K/Akt Signaling in MCF‐10A Cells , 2014, Journal of cellular biochemistry.
[77] Yan Wang,et al. The novel targets of DL-3-n-butylphthalide predicted by similarity ensemble approach in combination with molecular docking study. , 2017, Quantitative imaging in medicine and surgery.
[78] Xia Lin,et al. The Small C-terminal Domain Phosphatase 1 Inhibits Cancer Cell Migration and Invasion by Dephosphorylating Ser(P)68-Twist1 to Accelerate Twist1 Protein Degradation* , 2016, The Journal of Biological Chemistry.
[79] Jingliang Cheng,et al. Thymoquinone inhibits cancer metastasis by downregulating TWIST1 expression to reduce epithelial to mesenchymal transition , 2015, Oncotarget.
[80] C. Lima,et al. Genetic and structural analysis of the essential fission yeast RNA polymerase II CTD phosphatase Fcp1 , 2015, RNA.
[81] Pedro H M Torres,et al. Key Topics in Molecular Docking for Drug Design , 2019, International journal of molecular sciences.
[82] Lei Xie,et al. Structure-based systems biology for analyzing off-target binding. , 2011, Current opinion in structural biology.
[83] Matthew P. Repasky,et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.
[84] Stefan Paula,et al. Comparison of current docking tools for the simulation of inhibitor binding by the transmembrane domain of the sarco/endoplasmic reticulum calcium ATPase. , 2010, Biophysical chemistry.
[85] Jin Zhang,et al. Toward a Benchmarking Data Set Able to Evaluate Ligand- and Structure-based Virtual Screening Using Public HTS Data , 2015, J. Chem. Inf. Model..
[86] R. Gelber,et al. First--select the target: better choice of adjuvant treatments for breast cancer patients. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[87] Richard D. Taylor,et al. Modeling water molecules in protein-ligand docking using GOLD. , 2005, Journal of medicinal chemistry.
[88] Yan Zhang,et al. Determinants for dephosphorylation of the RNA polymerase II C‐terminal domain by Scp1 , 2006, Molecular cell.
[89] Louis-Philippe Morency,et al. Large-scale detection of drug off-targets: hypotheses for drug repurposing and understanding side-effects , 2017, BMC Pharmacology and Toxicology.
[90] T. Blundell,et al. Probing the druggability of protein-protein interactions: targeting the Notch1 receptor ankyrin domain using a fragment-based approach. , 2011, Biochemical Society transactions.
[91] J. Bolla,et al. The Research of New Inhibitors of Bacterial Methionine Aminopeptidase by Structure Based Virtual Screening Approach of ZINC DATABASE and In Vitro Validation , 2020 .
[92] Liliane Mouawad,et al. vSDC: a method to improve early recognition in virtual screening when limited experimental resources are available , 2016, Journal of Cheminformatics.
[93] I. Ghosh,et al. Molecules that Target beta‐Amyloid , 2007, ChemMedChem.
[94] Andrej Sali,et al. Virtual ligand screening against comparative protein structure models. , 2012, Methods in molecular biology.
[95] A. Bonen,et al. Fatty acid transport and transporters in muscle are critically regulated by Akt2 , 2015, FEBS letters.
[96] P. Lin,et al. A Novel RNA Polymerase II C-terminal Domain Phosphatase That Preferentially Dephosphorylates Serine 5* , 2003, Journal of Biological Chemistry.
[97] F. Cheng,et al. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2 , 2020, Cell Discovery.
[98] Matthew L. Danielson,et al. Computer-aided drug design platform using PyMOL , 2011, J. Comput. Aided Mol. Des..
[99] M. Mezei,et al. Molecular docking: a powerful approach for structure-based drug discovery. , 2011, Current computer-aided drug design.
[100] J. Pratap,et al. Role of Runx2 in IGF-1Rβ/Akt- and AMPK/Erk-dependent growth, survival and sensitivity towards metformin in breast cancer bone metastasis , 2016, Oncogene.
[101] Yan Xia,et al. Predicting protein targets for drug-like compounds using transcriptomics , 2018, bioRxiv.
[102] Docking to large allosteric binding sites on protein surfaces. , 2010, Advances in experimental medicine and biology.
[103] B. Nilius,et al. Pharmacology of Vanilloid Transient Receptor Potential Cation Channels , 2009, Molecular Pharmacology.
[104] Anton Meinhart,et al. Structure and mechanism of RNA polymerase II CTD phosphatases. , 2004, Molecular cell.
[105] J. Fraczek,et al. Toxicological and metabolic considerations for histone deacetylase inhibitors , 2013, Expert opinion on drug metabolism & toxicology.
[106] E. Raymond,et al. Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors. , 2010, Endocrinology and metabolism clinics of North America.
[107] Sally R. Ellingson,et al. Multi-conformer ensemble docking to difficult protein targets. , 2015, The journal of physical chemistry. B.
[108] Wen Peng,et al. Targeting cancer stem cell pathways for cancer therapy , 2020, Signal Transduction and Targeted Therapy.
[109] Hege S. Beard,et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.
[110] Wolfgang Jahnke,et al. Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases. , 2014, Future medicinal chemistry.
[111] J. Tainer,et al. Screening a peptidyl database for potential ligands to proteins with side‐chain flexibility , 1998, Proteins.
[112] Young Jun Kim,et al. Structure-Based Virtual Screening of Protein Tyrosine Phosphatase Inhibitors: Significance, Challenges, and Solutions. , 2017, Journal of microbiology and biotechnology.
[113] G. Keserű,et al. Ensemble docking-based virtual screening yields novel spirocyclic JAK1 inhibitors. , 2016, Journal of molecular graphics & modelling.
[114] Young Jun Kim,et al. Peripheral Inhibition of Small C‐Terminal Domain Phosphatase 1 With Napthoquinone Analogs , 2020 .
[115] Hackyoung Kim,et al. The diverse roles of RNA polymerase II C-terminal domain phosphatase SCP1 , 2014, BMB reports.
[116] T. Klabunde,et al. Structure-based drug discovery using GPCR homology modeling: successful virtual screening for antagonists of the alpha1A adrenergic receptor. , 2005, Journal of medicinal chemistry.
[117] X. Zou,et al. Ensemble docking of multiple protein structures: Considering protein structural variations in molecular docking , 2006, Proteins.
[118] S. Pfaff,et al. Small CTD Phosphatases Function in Silencing Neuronal Gene Expression , 2005, Science.
[119] Andrew J. Doig,et al. Properties of Protein Drug Target Classes , 2015, PloS one.
[120] Arthur Christopoulos,et al. Functional Selectivity and Classical Concepts of Quantitative Pharmacology , 2007, Journal of Pharmacology and Experimental Therapeutics.
[121] Ruben Abagyan,et al. Structure-Based Ligand Discovery Targeting Orthosteric and Allosteric Pockets of Dopamine Receptors , 2013, Molecular Pharmacology.
[122] S. Singh,et al. Identification of Dual negative allosteric modulators of Group I mGluR family: A shape based screening, ADME Prediction, Induced Fit Docking and Molecular Dynamics approach against Neurodegenerative Diseases. , 2019, Current topics in medicinal chemistry.
[123] Q. Wei,et al. Polymorphisms in the AKT1 and AKT2 genes and oesophageal squamous cell carcinoma risk in an Eastern Chinese population , 2016, Journal of cellular and molecular medicine.
[124] Yuko Okamoto,et al. Ligand docking simulations by generalized-ensemble algorithms. , 2013, Advances in protein chemistry and structural biology.
[125] Glen E Kellogg,et al. How to deal with low-resolution target structures: using SAR, ensemble docking, hydropathic analysis, and 3D-QSAR to definitively map the αβ-tubulin colchicine site. , 2013, Journal of medicinal chemistry.
[126] A. Mandell,et al. Designing allosteric peptide ligands targeting a globular protein. , 2007, Biopolymers.
[127] G. Terstappen,et al. How to Achieve Confidence in Drug Discovery and Development: Managing Risk (from a Reductionist to a Holistic Approach) , 2009, ChemMedChem.
[128] M. A. Afanasyeva,et al. Tumor suppressor properties of the small C-terminal domain phosphatases in non-small cell lung cancer , 2019, Bioscience reports.
[129] Y. Bahk,et al. A study of substrate specificity for a CTD phosphatase, SCP1, by proteomic screening of binding partners. , 2014, Biochemical and biophysical research communications.
[130] Benjamin P. Cossins,et al. Small Molecule Targeting of Protein–Protein Interactions through Allosteric Modulation of Dynamics , 2015, Molecules.
[131] C L Verlinde,et al. Structure-based drug design: progress, results and challenges. , 1994, Structure.
[132] Jonathan W. Essex,et al. Ensemble Docking into Multiple Crystallographically Derived Protein Structures: An Evaluation Based on the Statistical Analysis of Enrichments , 2010, J. Chem. Inf. Model..
[133] Ruben Abagyan,et al. Docking and scoring with ICM: the benchmarking results and strategies for improvement , 2012, Journal of Computer-Aided Molecular Design.
[134] Yingkai Zhang,et al. Computational Strategy for Bound State Structure Prediction in Structure-Based Virtual Screening: A Case Study of Protein Tyrosine Phosphatase Receptor Type O Inhibitors , 2018, J. Chem. Inf. Model..
[135] Mauricio O. Carneiro,et al. A Low-Frequency Inactivating AKT2 Variant Enriched in the Finnish Population Is Associated With Fasting Insulin Levels and Type 2 Diabetes Risk , 2017, Diabetes.
[136] J. Kim,et al. Akt regulates Progesterone Receptor B dependent transcription and angiogenesis in endometrial cancer cells , 2016, Oncogene.
[137] Jian Wang,et al. Computational investigation of imidazopyridine analogs as protein kinase B (Akt1) allosteric inhibitors by using 3D-QSAR, molecular docking and molecular dynamics simulations , 2019, Journal of biomolecular structure & dynamics.
[138] J. Dixon,et al. Structural and functional analysis of the phosphoryl transfer reaction mediated by the human small C‐terminal domain phosphatase, Scp1 , 2010, Protein science : a publication of the Protein Society.
[139] M. Tiwari,et al. Variable selection based QSAR modeling on Bisphenylbenzimidazole as Inhibitor of HIV-1 reverse transcriptase. , 2013, Medicinal chemistry (Shariqah (United Arab Emirates)).
[140] W. Wang,et al. SCP1 regulates c-Myc stability and functions through dephosphorylating c-Myc Ser62 , 2016, Oncogene.
[141] Todd J. A. Ewing,et al. DOCK 4.0: Search strategies for automated molecular docking of flexible molecule databases , 2001, J. Comput. Aided Mol. Des..
[142] Gail Mandel,et al. C-terminal domain small phosphatase 1 and MAP kinase reciprocally control REST stability and neuronal differentiation , 2014, Proceedings of the National Academy of Sciences.
[143] M. Tang,et al. SCP phosphatases suppress renal cell carcinoma by stabilizing PML and inhibiting mTOR/HIF signaling. , 2014, Cancer research.
[144] Svetlana A. Varentsova,et al. Essential Limitations of the Standard THz TDS Method for Substance Detection and Identification and a Way of Overcoming Them , 2016, Sensors.
[145] Alexandre M J J Bonvin,et al. Information-Driven, Ensemble Flexible Peptide Docking Using HADDOCK. , 2017, Methods in molecular biology.
[146] X. Barril,et al. Virtual screening in structure-based drug discovery. , 2004, Mini reviews in medicinal chemistry.
[147] Shaoyong Lu,et al. The Mechanism of Allosteric Inhibition of Protein Tyrosine Phosphatase 1B , 2014, PloS one.
[148] Xin Zhou,et al. PI3K/Akt signaling requires spatial compartmentalization in plasma membrane microdomains , 2011, Proceedings of the National Academy of Sciences.
[149] György M. Keserü,et al. Ensemble Docking into Flexible Active Sites. Critical Evaluation of FlexE against JNK-3 and beta-Secretase , 2006, J. Chem. Inf. Model..
[150] G. Krishnamurthy Rajanikant,et al. Ensemble pharmacophore meets ensemble docking: a novel screening strategy for the identification of RIPK1 inhibitors , 2014, Journal of Computer-Aided Molecular Design.
[151] J. Dixon,et al. UBLCP1 is a 26S proteasome phosphatase that regulates nuclear proteasome activity , 2011, Proceedings of the National Academy of Sciences.